Room-temperature vaccines could halve global waste, early trials show

Half the world's vaccines never reach an arm. They sit in storage facilities and transport containers, degrading in the heat or freezing in the cold, until someone throws them away. The World Health Organization estimates that roughly fifty percent of all vaccines manufactured globally end up as waste—a staggering loss of medicine that could have saved lives, especially in places where refrigeration is a luxury rather than a given.

Now, for the first time, British scientists have shown that this waste might not be inevitable. Researchers at the UK's National Institute for Health and Care Research have successfully kept a tetanus-diphtheria vaccine stable at room temperature for an entire year by converting it into a dry powder, then reconstituting it with water before injection. In a trial involving sixty volunteers, the powder version produced immune responses equivalent to the conventional refrigerated vaccine and was well tolerated with no safety concerns. The finding, published in eClinicalMedicine, suggests a path toward what the World Health Organization calls a "fridge-free" vaccine—one that survives at thirty degrees Celsius with seventy-five percent humidity.

The breakthrough hinges on an unlikely source of inspiration: resurrection plants. These organisms dry out completely during droughts, appearing dead, then spring back to life when rain returns. The secret lies in trehalose, a sugar the plants produce in massive quantities to stabilize their cells during dehydration. Researchers applied the same principle to the vaccine, using trehalose to protect the vaccine's vital components as it dried into powder form. The result is a vaccine that no longer depends on the fragile infrastructure of refrigeration—the "cold chain" that has constrained global immunization efforts for decades.

The cold chain is a particular burden in the world's poorest regions and most remote areas, where electricity is unreliable and refrigerators are scarce. In war zones, the challenge becomes even more acute. Jonathan Van-Tam, the former deputy chief medical officer for England and now an advisor to Stablepharma, the company behind the research, recalls the anxiety of transporting vaccines through inhospitable terrain in cool boxes, never certain whether the cold chain would hold long enough to reach waiting children. A room-temperature vaccine would eliminate that uncertainty entirely.

The research team has documented that their vaccine survives not just steady warmth but also dramatic temperature swings—cycling between minus twenty degrees Celsius and plus forty degrees Celsius. This resilience matters in the real world, where vaccines might spend hours in a cold aircraft hold, then hours more in the back of a truck under the sun. The larger trial, involving one hundred sixty people, is set to begin in the coming months. Because the original tetanus-diphtheria vaccine is already approved and licensed, researchers do not need to conduct the massive trials required for entirely new vaccines—a significant advantage that could accelerate the path to deployment.

Vaccine waste stems from multiple causes: damage in transport, expiration dates passing, unused doses from multi-dose vials. But cold chain failures remain a major culprit. The innovation cannot yet be applied to newer mRNA vaccines, which require different stabilization approaches. However, many existing vaccines could be adapted using trehalose, as could some medicines like monoclonal antibodies that currently demand refrigeration. Tuck Seng Wong, director of the UK-Southeast Asia Vaccine Manufacturing Research Hub, called the work "very exciting" and "a significant breakthrough," though he noted that questions remain about how the vaccine performs in larger, more ethnically diverse populations and how it holds up under real-world temperature fluctuations.

For Unicef, which coordinates immunization programs across the globe, the implications are profound. Ephrem Tekle Lemango, the organization's associate director of immunization, framed the innovation as a potential tool to reach millions more children and build more sustainable, equitable vaccination programs. The founder of Stablepharma, Bruce Roser, used similar language: a game-changer for global health, a way to deliver life-saving vaccines to people wherever they live. The next phase of testing will determine whether the promise holds.